Business Context and Reporting Period
Company: UPEXI, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: February 6, 2026 (Event Date); February 9, 2026 (Closing Date)
Context: The Company announced and closed a registered direct offering of common stock and warrants to a single institutional investor.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $7.4 million from the sale of 6,337,000 shares and accompanying warrants.
- Potential Additional Proceeds: Up to $9.5 million upon cash exercise of warrants.
- Offering Price: $1.17 per share of Common Stock and accompanying Warrant.
- Warrant Terms:
- Quantity: 6,337,000 warrants.
- Exercise Price: $1.50 per share.
- Expiration: 5 years from issuance.
- Redemption Price: $5.00 per share.
- Transaction Costs:
- Placement Agent Fee: 5.0% of gross proceeds (plus 5.0% on warrant exercises).
- Expense Reimbursement: Up to $75,000 for legal fees and $25,000 for non-accountable expenses.
Material Changes and Agreements
Amendment to Existing Warrants: In connection with the offering, warrants issued on December 1, 2025 (covering 3,289,474 shares) were amended:
- Exercise Price Reduction: Lowered from $4.00 to $2.83 per share.
- Redemption Trigger Reduction: Lowered from $8.50 to $7.00 per share.
Lock-Up Agreements: Directors and executive officers are restricted from selling or transferring shares for 15 days following the closing, subject to customary exceptions (including existing at-the-market sales agreements).
Guidance, Outlook, and Risks
Management Commentary: The filing focuses on the execution of the capital raise and does not provide specific operational guidance or forward-looking financial projections beyond the potential warrant exercise proceeds.
Risks and Contingencies:
- Dilution: The issuance of 6,337,000 new shares and potential warrant exercises will dilute existing shareholders.
- Market Restrictions: The Company is subject to a 15-day standstill on issuing new equity without consent, limiting immediate flexibility for further capital raises.
- Warrant Redemption: The Company retains the right to redeem warrants at $5.00 per share, which may impact investor behavior.
Investor Verification Checklist
- Verify the net proceeds after deducting the 5% placement fee and estimated offering expenses.
- Review the full text of the Amended Warrant (Exhibit 4.2) to confirm the impact of the reduced exercise price on existing warrant holders.
- Confirm the Company's current cash position and liquidity needs post-closing.
- Monitor the 15-day lock-up period expiration for potential selling pressure from insiders.
- Check the prospectus supplement filed on February 9, 2026, for detailed risk factors associated with the offering.